However, the regulation of genes involved in the degradation of the extracellular matrix (ECM), in particular ADAM19 (ADAM Metallopeptidase Domain 19) coding a metallopeptidase, was strongly regulated by epigenetics during EMT, independently of the EMT model, and we showed that epigenetic modifications were crucial for EMT in these cancer models. This evidence concerns the gene ADAM19 and cancer.